Our findings highlight host autophagy, and in particular ATG16L1, as an emerging target for HIV-1 therapies, underscoring the relevancy of repurposing clinically-approved autophagy drugs to restore immune function in chronic HIV-1 infection. Here, ATG16L1 is linked to HIV-1 infection.